Publications by authors named "A Clucas"
Article Synopsis
- Nemolizumab is a treatment targeting the IL-31 receptor α subunit, which plays a role in atopic dermatitis (AD), aiming to improve symptoms in patients with moderate-to-severe AD.
- In a 24-week study involving 226 adult participants, different dosages of nemolizumab were compared to a placebo, showing significant improvements in skin severity and itch scores, particularly with the 30 mg dose.
- Results showed that the 30 mg nemolizumab group experienced the greatest symptom reduction by week 24, while the treatment was generally well tolerated, with mild side effects like nasopharyngitis reported.
We assessed the effects of post-exercise cold-water immersion (CWI) in modulating PGC-1α mRNA expression in response to exercise commenced with low muscle glycogen availability. In a randomized repeated-measures design, nine recreationally active males completed an acute two-legged high-intensity cycling protocol (8 × 5 min at 82.5% peak power output) followed by 10 min of two-legged post-exercise CWI (8°C) or control conditions (CON).
View Article and Find Full Text PDFSebum excretion has generally been accepted as an important factor in the development of acne vulgaris. However, the relationship of sebum excretion and acne outcome has not yet been clearly demonstrated quantitatively. The objective of this analysis was to explore the correlation of sebum and acne by combining data from studies of various acne treatments that have demonstrated effects on both sebum excretion and acne outcome.
View Article and Find Full Text PDFBackground: The CC-chemokine receptor-1 (CCR1) is thought to be involved in recruitment of inflammatory cells in allergic contact dermatitis (ACD). CP-481715 is a specific antagonist of CCR1.
Objectives: To determine the inhibitory effects of CP-418 715 in ACD by evaluating the clinical signs and cellular infiltration in skin biopsies following epicutaneous nickel challenge in allergic subjects.